Share Your Comments About Hazardous Drugs With NIOSH
As part of the update process for the List of Hazardous Drugs in Healthcare Settings, the National Institute for Occupational Safety and Health (NIOSH) of the Centers for Disease Control and Prevention (CDC), in the Department of Health and Human Services, is seeking public comments (https://www.federalregister.gov/documents/2020/05/01/2020-09332/hazardous-drugs-draft-niosh-list-of-hazardous-drugs-in-healthcare-settings-2020-procedures-and-risk) on the draft documents through July 30, 2020.
Three separate documents (https://www.regulations.gov/docket?D=CDC-2020-0046) are open for public comment:
- NIOSH Procedures for Developing the List of Hazardous Drugs in Healthcare Settings
- NIOSH List of Hazardous Drugs in Healthcare Settings, 2020 (includes drugs proposed for new placement on the 2020 list)
- Managing Hazardous Drug Exposures: Information for Healthcare Settings
In addition to general feedback, NIOSH is seeking comments specifically on the following questions:
- Which unique ingredient identifier is the most useful when using the list?
- Because of conflicting evidence about the hazard posed by botulinum toxins to the workers who handle these drugs, NIOSH is not proposing the placement of botulinum toxins on the list at this time. What additional studies, data, and expert opinions would help NIOSH evaluate the botulinum toxins more fully in the future?
To submit your comments, identify docket numbers CDC-2020-0046 and NIOSH-233-C and follow the instructions at regulations.gov (http://www.regulations.gov/). Alternately, you can mail your comments to NIOSH Docket Office, Robert A. Taft Laboratories, MS-C34, 1090 Tusculum Avenue, Cincinnati, OH 45226-1998. All comments must be received by July 30, 2020.